官方服务：
资源简介：
TRAIL/IZI in Melanoma in 2 cell lines A375 and WM1346
应用场景：
创建时间：
2022-01-12
相关数据集
Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review
ABSTRACT Introduction: despite being extremely effective in some cases, up to 70% of patients with melanoma do not respond to anti-PD-1/PD-L1 (primary resistance) and many of the responders eventually
DataCite Commons2023-05-20 更新110
Synthetic lethal screening with small molecule inhibitors provides a pathway to rational combination therapies for melanoma
Recent data demonstrate that extracellular signals are transmitted through a network of proteins rather than hierarchical signaling pathways. This network model suggests why inhibition of a single com
NIAID Data Ecosystem70
MelanoDB: A Database of clinical and molecular features of advanced melanoma patients treated with2 MAPK inhibitors
MAPK inhibitors have significantly improved overall survival in patients with metastatic melanoma disease but their efficacy is still limited by primary or acquired resistance. Several studies have at
NIAID Data Ecosystem40
Supplementary Tables – Treatment Patterns and Outcomes following Disease Progression on Anti-PD-1 Therapies for Advanced Melanoma
Supplemental Table 1. Treatment Patterns after Index Line for the Anti-programmed Cell Death-1-treated Patients with Advanced Melanoma Treated with a BRAF Therapy in the Index Line or Pri
DataCite Commons2024-02-14 更新90
Supplementary Material for: Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF -V600 + MEK Inhibitors for Advanced Melanoma
Background: Combined treatment with BRAF -V600 and MEK inhibitors has significantly improved progression-free and overall survival of patients with BRAF -mutated melanoma. Pa
DataCite Commons2020-08-28 更新70
